JANX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.659

+83.08%

-0.707

+85.97%

-0.753

+36.97%

Estimates Revision

The market is revising Upward the revenue expectations for Janux Therapeutics, Inc. (JANX) for FY2025, with the revenue forecasts being adjusted by 184.91% over the past three months. During the same period, the stock price has changed by -35.41%.

Revenue Estimates for FY2025

Revise Upward

+184.91%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-11.92%

In Past 3 Month

Stock Price

Go Down

-35.41%

In Past 3 Month

14 Analyst Rating

Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 77.09 USD with a low forecast of 42.00 USD and a high forecast of 200.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

1 Hold

0 Sell

Strong Buy

Current: 15.120

Low

42.00

Averages

77.09

High

200.00

Current: 15.120

Low

42.00

Averages

77.09

High

200.00

Stifel

Stephen Willey

Buy

downgrade

$46 -> $38

2025-12-02

Reason

Stifel

Stephen Willey

Price Target

$46 -> $38

2025-12-02

downgrade

Buy

Reason

Stifel analyst Stephen Willey lowered the firm's price target on Janux Therapeutics to $38 from $46 and keeps a Buy rating on the shares. The firm sees "some positives to extract" from Monday's JANX007 Phase 1 update, but also questions, the analyst tells investors. While acknowledging the near-term catalyst calendar "doesn't set-up great," the firm adds that it "struggles to rationalize" the 40% post-close attrition in shares given "platform validation in a thematically/strategically space."

Cantor Fitzgerald

Josh Schimmer

Overweight

downgrade

$200 -> $150

2025-12-02

Reason

Cantor Fitzgerald

Josh Schimmer

Price Target

$200 -> $150

2025-12-02

downgrade

Overweight

Reason

Cantor Fitzgerald analyst Josh Schimmer lowered the firm's price target on Janux Therapeutics to $150 from $200 and keeps an Overweight rating on the shares. The new data for JANX007 addresses a number of key important questions, but also leaves a handful of remaining variables and blanks to fill in, and doesn't provide timelines for next clinical or regulatory updates, the analyst tells investors in a research note. Still, Cantor thinks the selloff is overdone, setting up for a compelling entry point.

Clear Street

Buy

downgrade

$80 -> $32

2025-12-02

Reason

Clear Street

Price Target

$80 -> $32

2025-12-02

downgrade

Buy

Reason

Clear Street lowered the firm's price target on Janux Therapeutics to $32 from $80 and keeps a Buy rating on the shares. The firm cites "more pragmatic" market entry timelines for the target cut. It views the updated Phase 1 data for JANX007 as highlighting a "thoughtful development process."

H.C. Wainwright

Buy

downgrade

$70 -> $45

2025-12-02

Reason

H.C. Wainwright

Price Target

$70 -> $45

2025-12-02

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Janux Therapeutics to $45 from $70 and keeps a Buy rating on the shares after the company announced updated interim results from its ongoing Phase 1 study evaluating JANX007 in metastatic castration-resistant prostate cancer. The overall efficacy profile deteriorated on key endpoints, the analyst tells investors in a research note. H.C. Wainwright believes the JANX007 update "were mixed," and feels the drug will likely be a "show me" story until the dataset matures.

BofA

Buy

downgrade

$58 -> $49

2025-12-02

Reason

BofA

Price Target

$58 -> $49

2025-12-02

downgrade

Buy

Reason

BofA lowered the firm's price target on Janux Therapeutics to $49 from $58 and keeps a Buy rating on the shares after the company announced updated interim data for JANX007 from the Phase 1 clinical program in patients with mCRPC. The firm still thinks '007 is "a viable drug with a reasonable safety profile and the potential to show a benefit in OS over Pluvicto," says the analyst, who views the 43% move lower in shares as "overdone" despite calling the latest Phase 1 update "admittedly mixed." The firm lowers its price target as it pushes back expectations for a JANX007 launch to 2028 and reduces its peak market share estimate to 15% from 20%.

Wolfe Research

Peer Perform

initiated

2025-11-17

Reason

Wolfe Research

Price Target

2025-11-17

initiated

Peer Perform

Reason

Wolfe Research initiated coverage of Janux Therapeutics with a Peer Perform rating and no price target. The firm believes additional work may be needed on JANX-007 before strong durability data materialize, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Janux Therapeutics Inc (JANX.O) is -5.25, compared to its 5-year average forward P/E of -15.48. For a more detailed relative valuation and DCF analysis to assess Janux Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-15.48

Current PE

-5.25

Overvalued PE

-4.38

Undervalued PE

-26.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.18

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.47

Undervalued EV/EBITDA

-16.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

508.42

Current PS

0.00

Overvalued PS

960.56

Undervalued PS

56.29

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 575.67% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

JANX News & Events

Events Timeline

No data

News

5.0

12-04NASDAQ.COM

Janux Executive Sells 16,665 Shares for $501,000 Through Options Exercise

4.0

12-03NASDAQ.COM

Stifel Continues to Recommend Buy for Janux Therapeutics (JANX)

4.5

12-02Benzinga

Gold Declines More Than 1%; Signet Stock Drops Following Q3 Earnings Report

People Also Watch

Frequently Asked Questions

What is Janux Therapeutics Inc (JANX) stock price today?

The current price of JANX is 15.12 USD — it has decreased -1.18 % in the last trading day.

What is Janux Therapeutics Inc (JANX)'s business?

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

What is the price predicton of JANX Stock?

What is Janux Therapeutics Inc (JANX)'s revenue for the last quarter?

Janux Therapeutics Inc revenue for the last quarter amounts to 10.00M USD, increased 2177.90 % YoY.

What is Janux Therapeutics Inc (JANX)'s earnings per share (EPS) for the last quarter?

Janux Therapeutics Inc. EPS for the last quarter amounts to -0.39 USD, decreased -23.53 % YoY.

What changes have occurred in the market's expectations for Janux Therapeutics Inc (JANX)'s fundamentals?

How many employees does Janux Therapeutics Inc (JANX). have?

Janux Therapeutics Inc (JANX) has 74 emplpoyees as of December 16 2025.

What is Janux Therapeutics Inc (JANX) market cap?

Today JANX has the market capitalization of 909.43M USD.